[Modern approaches to the retinitis pigmentosa treatment in the older age patients (literature review).]

Retinitis pigmentosa is a hereditary degenerative retina disease, often severe and affecting the retinal pigment epithelium and photoreceptor layer. For the older age group, the disease is increased by the addition of age-related degenerative processes in the retina. Due to the diversity of development factors and forms of retinitis pigmentosa, there is no uniform concept for treating a disease. Applying gene therapy and the optogenetic method is currently impossible because they are at the stage of experimental studies. For patients with terminal stage of retinitis pigmentosa, the implantation of a bionic eye is possible - a device with the ability to restore residual vision. The main treatment method is therapeutic. There were a lot of experimental and clinical studies of various drugs, the efficiency of which varies. Peptide bioregulators are actively used, they support the structural and functional homeostasis of cell populations and have a retinoprotective effect. It is also particularly important to improve the somatic condition of the patient through the use of peptide drugs in the complex.